Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

NIAAA to study gabapentin enacarbil for the treatment of alcohol use disorder

Sep. 12, 2014

NIDA awards grant to support completion of phase IIa trial of ibudilast in opioid dependence

Sep. 9, 2014

Cleveland BioLabs clear to submit pre-EUA for entolimod

Sep. 4, 2014

Aldea Pharmaceuticals closes Series B financing

Aug. 26, 2014

Aeolus files IND for acute radiation syndrome candidate AEOL-10150

Aug. 22, 2014

MediciNova discloses results from phase IIa study of ibudilast in opioid dependence

Aug. 20, 2014

NIPER reports novel PON 1 enzymes

Aug. 14, 2014

Lightlake Therapeutics receives funding for development of intranasal naloxone

Aug. 5, 2014

Evzio auto-injector available in the U.S. for emergency treatment of opioid overdose

July 11, 2014

Presentation of data on Aeolus' AEOL-10150 medical countermeasure

July 4, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...